AIJIEWEI^® has passed consistency evaluation and entered the fourth national VBP. It blocks the JAK signal pathway by intracellular targeting and regulates various inflammatory factors associated with Ra, achieves potent and rapid improvement of traditional DMARDs in rheumatoid arthritis patients with poor efficacy, and is recommended by Chinese and International Authority RA guidelines.